XML 200 R16.htm IDEA: XBRL DOCUMENT
v3.26.1

Accounts Payable and Accrued Expenses | 9 Months Ended | 12 Months Ended
--- | --- | ---
Feb. 28, 2026 | Dec. 31, 2025 | May 31, 2025
Accounts Payable and Accrued Expenses [Line Items] |  |  |
ACCOUNTS PAYABLE AND ACCRUED EXPENSES |  | 10. ACCOUNTS PAYABLE AND ACCRUED EXPENSES Accounts payable and accrued expenses as of December 31, 2025 and 2024 consisted of:
|  | December 31, 2025 |  | December 31, 2024
Research and development expenses payable |  | $ | 830,189 |  | $ | 778,205
Professional fees payable |  |  | 185,247 |  |  | 127,031
Others |  |  | 56,279 |  |  | 13,375
|  | $ | 1,071,715 |  | $ | 918,611
DiamiR Biosciences Corp. [Member] |  |  |
Accounts Payable and Accrued Expenses [Line Items] |  |  |
ACCOUNTS PAYABLE AND ACCRUED EXPENSES | NOTE 7 — ACCOUNTS PAYABLE AND ACCRUED EXPENSES Accounts payable and accrued expenses consist of the following:
|  | February 28, 2026 |  | May 31, 2025
Outside services |  | $ | 680,775 |  | $ | 220,411
Employee compensation |  |  | 8,703 |  |  | 5,884
Other |  |  | 10,364 |  |  | 5,563
Total |  | $ | 699,842 |  | $ | 231,858
|  | NOTE 7 — ACCOUNTS PAYABLE AND ACCRUED EXPENSES Accounts payable and accrued expenses consist of the following:
|  | May 31, 2025 |  | May 31, 2024
Outside services |  | $ | 220,411 |  | $ | 123,065
Employee compensation |  |  | 5,884 |  |  | 12,285
Other |  |  | 5,563 |  |  | 13,298
Total |  | $ | 231,858 |  | $ | 148,648

X
- References No definition available. + Details
Name: | apm_AccountsPayableandAccruedExpensesLineItems
Namespace Prefix: | apm_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 720 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details
Name: | us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_ConsolidatedEntitiesAxis=apm_DiamiRBiosciencesCorpMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |